| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Aclarion, Inc. Common Stock$2.64
-0.02 (-0.75%)
F 13Pipeline Score Tools & Services · Clinical
Market Cap
7.37 M
EPS
-17.21
P/E Ratio
-0.19 $
Value Trade
190.92 K
SEC Financials
Q1 2026Dilution Risk
Revenue
21.14 K
R&D Expenses
315.42 K
Operating CF
-2.64 M
Total Assets
20.64 M
Total Liabilities
986.21 K
Equity
19.65 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
19.00 M
Monthly Burn
881.00 K
Runway
19.5 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
18.88 K
52 Week Range
2.34 - 12.03
% held by Insiders
27.01 %
% held by Institutions
4.57 %
Enterprise Value
-4.67 M
Total Shares
2.46 M
Short %
3.03 %
Float Shares
2.42 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F13
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 10%
Micro Cap (rank 822 of 912)
Percentile RankAclarion, Inc. Common Stock has significant pipeline risk (13/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ACON
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ACON Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-ACON
Jul 7, 2026Aclarion Announces Texas Spine Care Center as New CLARITY Site
Aclarion, Inc. has announced the Texas Spine Care Center as a new site for its CLARITY trial, which evaluates the Nociscan technology for chronic low back pain. The trial aims to demonstrate Nociscan's effectiveness in improving surgical outcomes. Texas Spine Care's commitment to identifying pain sources aligns with Nociscan's capabilities. The study will involve 300 patients and aims for initial results by Q4 2026.
Read more →-ACON
Jun 10, 2026Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub
Aclarion, Inc. will present at the Planet MicroCap Las Vegas 2026 on June 17, 2026. The company is experiencing significant growth in its Nociscan platform, which aids in diagnosing chronic low back pain. Key highlights include an anticipated interim readout from the CLARITY trial and a $2.5 million share repurchase program. The presentation will be hosted by Executive Chairman Jeff Thramann.
Read more →-ACON
Jun 9, 2026Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform
Aclarion has partnered with PRIA Healthcare to enhance the reimbursement and commercial adoption of its AI-powered Nociscan platform for chronic low back pain. This Market Access Program aims to replicate the success of reimbursement wins in the UK, facilitating patient access and supporting healthcare providers in assessing the platform's clinical value. The collaboration is expected to streamline the reimbursement process and generate insights into payer dynamics.
Read more →-ACON
Jun 3, 2026Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
Aclarion, Inc. has partnered with the Institute of Neuro Innovation to enhance the availability of its Nociscan platform in the Los Angeles area. This collaboration aims to generate real-world evidence by comparing Nociscan's chemical biomarker data with SPECT-CT bone metabolic information. The partnership supports Aclarion's growth strategy while providing critical insights for treating chronic low back pain.
Read more →-ACON
Apr 30, 2026Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
Aclarion, Inc. reported a strong Q1 2026 with a 196% increase in Nociscan scan volumes, indicating accelerated adoption. The company is advancing its reimbursement strategies and has a robust financial position with no debt. Aclarion anticipates significant market opportunities as it integrates Nociscan into clinical workflows and prepares for upcoming clinical trial readouts.
Read more →-ACON
Apr 28, 2026Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan
Aclarion, Inc. has appointed Daniel Keefe as the Commercial Director for the Western U.S. to enhance the adoption of its Nociscan technology. This move comes amid a significant increase in demand and utilization of Nociscan, which helps identify chronic low back pain sources. Keefe's extensive experience in the medical device industry is expected to bolster Aclarion's market presence.
Read more →-ACON
Apr 23, 2026▼ -12.6%on this newsshared move
Aclarion Announces $2.5 Million Stock Repurchase Plan
Aclarion, Inc. has announced a $2.5 million stock repurchase plan aimed at enhancing shareholder value while supporting the adoption of its Nociscan platform. The program will be executed over the next 12 months, depending on market conditions. Aclarion believes its current valuation does not fully reflect its growth potential, and the repurchase will be funded using existing cash reserves.
Read more →-ACON
Mar 19, 2026Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan
Aclarion, Inc. has announced the adoption of a limited duration stockholder rights plan, effective immediately and set to expire in one year. This plan is designed to ensure that stockholders can realize long-term value and to deter any entity from gaining control without offering an appropriate premium. The structure of the rights plan includes a preferred stock purchase right for each share of common stock and aims to provide the Board sufficient time to consider offers that align with shareholders' best interests. This strategic move is not in response to any specific acquisition attempt.
Read more →-ACON
Feb 5, 2026▼ -12.6%on this news
Aclarion Publishes 2026 Shareholder Letter from the Chairman
Aclarion, Inc. has released its 2026 Shareholder Letter, highlighting significant clinical and financial priorities. The company is set to report initial results from its 300-patient CLARITY trial by the end of Q3 2026. With a robust cash position extending into 2028, Aclarion aims to enhance shareholder value while advancing its innovative Nociscan technology for chronic low back pain.
Read more →-ACON
Feb 3, 2026Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation
Aclarion, Inc. has partnered with Source Healthcare to enhance the use of its Nociscan technology for chronic low back pain. This collaboration aims to fill a gap in pain management by providing real-world evidence comparing Nociscan with traditional anesthetic discography. Nociscan is a non-invasive tool that measures biomarkers related to spinal disc pain, showing promise in improving patient outcomes.
Read more →-ACON
Jan 13, 2026▼ -6.9%on this news
Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028
Aclarion, Inc. has successfully closed a $10.4 million financing round, significantly enhancing its financial stability and extending its operational runway into 2028. This capital raise will support the commercialization of its Nociscan technology, which aims to improve the diagnosis of chronic low back pain. The company is now positioned for long-term growth and strategic partnerships.
Read more →-ACON
Sep 3, 2025Aclarion Appoints Greg Gould as Chief Financial Officer HealthTech CFO with extensive public company experience building organizations for growth and value creation Demonstrated success in raising capital, driving profit
Aclarion, Inc. has appointed Greg Gould as its new Chief Financial Officer, effective immediately. Gould brings over 30 years of experience in public and private companies, with a successful history in raising capital and driving profitability. He takes over from John Lorbiecki, who is retiring after establishing a solid financial foundation for the company. Gould's leadership is expected to support Aclarion's goal of expanding the availability of its Nociscan technology for chronic low back pain diagnosis.
Read more →-ACON
Jul 7, 2025Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders Meeting adjourned to Monday
Aclarion, Inc. has announced the adjournment of its Annual Meeting of Stockholders originally scheduled for July 7, 2025, due to the need for additional vote solicitation. The meeting will be reconvened on July 21, 2025, at 9:30 a.m. Mountain Time at the company's corporate office. Stockholders who were eligible to vote as of May 9, 2025, are encouraged to vote or change their previously submitted proxies before the reconvened meeting.
Read more →-ACON
Apr 23, 2025Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025 Broomfield, CO
Aclarion, Inc. will present at the Planet MicroCap Showcase: VEGAS 2025, showcasing their advancements in healthcare technology for chronic low back pain. The updated investor presentation highlights the company's Nociscan platform, which uses Magnetic Resonance Spectroscopy and AI algorithms to assist physicians in identifying the source of pain in lumbar discs. CEO Brent Ness will discuss recent initiatives aimed at increasing the company's value at the event. This appearance emphasizes Aclarion's commitment to innovating in chronic pain diagnostics.
Read more →-ACON
Feb 28, 2025▲ +27.4%on this news· ran to +189% by day 1
Aclarion, Inc. Announces Adjournment of Special Meeting of Stockholders Meeting adjourned to Wednesday
Aclarion, Inc. has announced the adjournment of its Special Meeting of Stockholders, originally set for February 28, 2025. The meeting will reconvene on March 5, 2025, to solicit further votes on specific proposals. Stockholders who are eligible and voted previously are encouraged to participate again if they wish to change their decision. This adjournment reflects a need to ensure enough votes are obtained for the proposals outlined in the company's proxy statement.
Read more →-ACON
Jan 30, 2025Aclarion Announces Pricing of Registered Direct Offering of Common Stock Priced At the Market
Aclarion, Inc. has announced the pricing for a registered direct offering of common stock, selling 506,803 shares at $9.25 each, expected to raise approximately $4.7 million in gross proceeds. The funds will be allocated toward market development, clinical evidence, and product development, supporting their Nociscan platform aimed at chronic low back pain. Closing is anticipated around January 31, 2025, subject to customary conditions. The offering is made under a shelf registration previously filed with the SEC.
Read more →-ACON
Jun 26, 2024Aclarion Announces Initial Payer Coverage of Nociscan by AXA throughout Greater London, UK AXA is the 2 nd largest provider of private medical insurance in the UK. Payer coverage is the most important catalyst Aclarion c
Aclarion, Inc. has announced that AXA, the second largest provider of private medical insurance in the UK, has granted initial payer coverage for its Nociscan technology throughout Greater London. This coverage is a crucial development for Aclarion, as it will facilitate wider commercial efforts and improve patient access to necessary diagnostics for chronic low back pain. The partnership with AXA, alongside The London Clinic, signals a major validation of Aclarion's strategy in a sophisticated healthcare market, while more payer coverage decisions are anticipated soon.
Read more →-ACON
Feb 21, 2024Index to Financial Statements Aclarion, Inc. Page Financial Statements Report of Independent Registered Public Accounting Firm - Haynie & Company LLP (ID# 457) F-2 Report of Independent Registered Public Accounting Firm
Aclarion, Inc.'s recent financial statements revealed significant ongoing challenges, including recurring operating losses and a deficiency in shareholders' equity, which raises concerns about its ability to continue as a going concern. The independent auditor, Haynie & Company LLP, noted these issues in their report, emphasizing the uncertainty surrounding the company's financial stability. Additionally, the financial statements include a restatement of prior year figures to correct misstatements, indicating a lack of consistency in past reporting. Overall, these findings suggest a precarious financial position for Aclarion, Inc.
Read more →-ACON
Sep 28, 2023Better Data Better Care OCTOBER 2023 NASDAQ: ACON Aclarion 2023 2 Disclaimer The information in this material is provided for general information purposes only and does not take into account the investment objectives, fi
Aclarion, Inc. provides an overview of its technology, Nociscan, which aims to identify painful discs in patients suffering from chronic low back pain. The company highlights various studies that suggest Nociscan could lead to better surgical outcomes compared to traditional methods. Ongoing and future clinical trials are expected to evaluate the effectiveness of Nociscan in improving treatment results. The presentation also covers uncertainties and risks associated with the company's forward-looking statements and market expectations.
Read more →-ACON
Aug 25, 2023Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report BROOMFIELD, CO
Aclarion, Inc. announced it filed its delayed Quarterly Report for the period ending June 30, 2023, on August 25, 2023, after missing the August 21 deadline set by the SEC. The delay was attributed to the review process by its new independent accountant, CohnReznick LLP. Despite this setback, Aclarion's Nociscan platform continues to enable physicians in diagnosing chronic low back pain through advanced biomarker analysis.
Read more →-ACON
May 19, 2023Aclarion, Inc. Announces Delayed 10-Q Filing BROOMFIELD, CO
Aclarion, Inc. has announced a delay in filing its Quarterly Report for the quarter ending March 31, 2023, due to the ongoing review process by its new independent accountant, CohnReznick LLP. The company also plans to file restated financial statements for the year ending December 31, 2022, and will file the Quarterly Report immediately after the restatement. While the company does not expect a prolonged delay, it cannot provide a specific date for the filing. The financial restatement is noted to have no impact on the company’s cash position or liquidity.
Read more →-ACON
Oct 25, 2022Aclarion, Inc. Releases Updated Investor Presentation In Connection with Appearance at LD Micro Main Event
Inc. Releases Updated Investor Presentation Connection with Appearance at BROOMFIELD, CO October 25, 2022 / Aclarion, Inc. (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and proprietary augmented int
Read more →-ACON
Apr 21, 2022Aclarion, Inc. Announces Listing on Nasdaq and Pricing of $9.4 Million Initial Public Offering Thursday
Aclarion, Inc. Announces Listing on Nasdaq and Pricing of $9.4 Million Initial Public Offering Thursday, April 21, 2022 7:45 PM SAN MATEO, CA / ACCESSWIRE / April 21, 2022 / Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology comp
Read more →Competitive Position
How ACON ranks across every disease it competes inCompetitive Position is a premium feature
See how ACON ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial